International Journal of Drug Delivery Technology
Volume 14, Issue 3

Synthesis, Characterization and Antibacterial Studies of New Crown Ether Prodrugs

Marwan Majeed Al-Lammi*, Raheem Jameel M, Layla Jasim Abbas

Basrah University, Pharmacy College, Pharmaceutical Chemistry Department, Basrah, Iraq. 

Received: 20th January, 2024; Revised: 27th February, 2024; Accepted: 11th July, 2024; Available Online: 25th September, 2024 

ABSTRACT

New three esters (E1, E2 and E3) from crown ethers and drugs were prepared by Stiglich esterification. These procedures began with the reaction of certain quinolones (levofloxacin, ciprofloxacin, and nalidixic acid) with thionyl chloride to produce a considerably more potent acylating agent. Next, for the production of ester prodrugs, 2-hydroxymethyl-15-crown-5 ether (a lariat crown ether) was esterified using an acid chloride in the presence of pyridine. These molecules were synthesized as carrier-mediated prodrugs in order to solve different pharmacokinetic and pharmacological difficulties, enhance physicochemical features, and augment the antibacterial efficacy of the parent drugs by structural modifications while avoiding bacterial resistance. The compounds` structures were verified by FTIR, UV, H1 & 13C-NMR spectroscopy and certain physiochemical qualities. In a concentration-dependent manner, all of the synthesized prodrugs’ biological studies revealed improved activity against certain bacterial species.

Keywords: Crown ether, Levofloxacin, Ciprofloxacin, Nalidixic acid, Antibacterial activity.

International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.3.42

How to cite this article: Al-Lammi MM, Jameel RM, Abbas LJ. Synthesis, Characterization and Antibacterial Studies of

New Crown Ether Prodrugs. International Journal of Drug Delivery Technology. 2024;14(3):1553-1559.

REFERENCES

  1. Swinburne, N. & Steed, J. W. Supramolecular Chemistry From Molecules to Nanomaterials: Podands. John Wiley & Sons, Ltd. 1-44 (2012). doi:10.1002/9780470661345.smc058.
  2. Vögtle, F. & Weber, E. Consequences of the ‘Pedersen papers’ on crown type chemistry at Würzburg and Bonn Universities: From heteroaromatic crowns and podands to large molecular and crystalline cavities including multisite receptors, cascade molecules, chromoionophores, siderop. J. Incl. Phenom. Mol. Recognit. Chem. 12, 75–119 (1992)..
  3. S. Dighe, S. R. Pattan, D. S. Musmade, M. B. Hole, V.Gaware, and P. A. Chavan, “Host-Guest Chemistry: An Overview,” Pharmacol. Newsl., vol. 1, pp. 943–963, 2010, [Online]. Available: http://pharmacologyonline.silae.it/files/ newsletter/2010/vol1/105.Dighe.pdf.
  4. Patil, R. et al. A thesaurus comprising brief introduction ofchemosensor for recognition of metal cations and anions. WorldPharm. Res. 6, 296–340 (2017).
  5. Gokel, W. et al. Lariat ethers: From cation complexation to supramolecular assemblies. Pure Appl. Chem. 60, 461–465 (1988).
  6. Klenc et al., “Synthesis of 4-Substituted 2- ( 4-Methylpiperazino)pyrimidines and Quinazoline Analogs as Serotonin 5-HT 2A Receptor Ligands,” J. Heterocycl. Chem., vol. 46, no. November,1259–1265, 2009, doi: 10.1002/jhet.
  7. Allouche, “Software News and Updates Gabedit — A Graphical User Interface for Computational Chemistry Softwares,” J. Comput. Chem., vol. 32, pp. 174–182, 2012, doi: 10.1002/jcc.
  8. Fabbrizzi, The Beginning of the Story: Crown Ethers. Cryptandsand Cryptates 1–9 (2018) doi:10.1142/9781786343703_0001.
  9. M. Master, M. E. Rodriguez, M. E. Kenney, N. L. Oleinick, andSen Gupta, “Delivery of the photosensitizer Pc 4 in PEG–PCLmicelles for in vitro PDT studies,” J. Pharm. Sci., vol. 99, no. 5,2386–2398, 2010, doi: 10.1002/jps.
  10. Farah et al., “Comparative analysis of biopharmaceutic classification system (BCS) based biowaiver protocols to validate equivalence of a multisource product,” African J. Pharm. Pharmacol., vol. 14, no. 7, pp. 212–220, 2020, doi: 10.5897/ ajpp2020.5130.
  11. K. Maraie, A. T. Alhamdany, and A. A. Radhi, “Efficacy of combination solid dispersion technology on dissolution performance of nalidixic acid and cefdinir,” Asian J. Pharm. Clin. Res., vol. 10, no. 4, pp. 394–401, 2017, doi: 10.22159/ajpcr.2017. v10i4.16913.
  12. M. Larsen and R. J. Johnson, “Microbial esterases and ester prodrugs: An unlikely marriage for combating antibiotic resistance,” Drug Dev. Res., vol. 80, no. 1, pp. 33–47, 2019, doi:10.1002/ddr.21468.
  13. S. Liu et al., “Impact of ester promoieties on transdermal delivery of ketorolac,” J. Pharm. Sci., vol. 103, no. 3, pp. 974–986, 2014, doi: 10.1002/jps.23888.
  14. Mizen and G. Burton, “The use of esters as prodrugs for oraldelivery of beta-lactam antibiotics.,” Pharm. Biotechnol., vol. 11,345–365, 1998, doi: 10.1007/0-306-47384-4_15.
  15. B. Lee et al., “Lipophilic activated ester prodrug approach for drug delivery to the intestinal lymphatic system,” J. Control. Release, vol. 286, no. July, pp. 10–19, 2018, doi: 10.1016/j. jconrel.2018.07.022.
  16. Zuffanti, “Preparation of acyl chlorides with thionyl chloride,” Chem. Educ., vol. 25, no. 9, p. 481, 1948, doi: 10.1021/ ed025p481.
  17. Piplani, A. Rana, and P. Sharma, “Prodrugs of Antiinfective Agents: A Review,” J. Pharm. Pharm. Sci., vol. 19, pp. 82–113, 2016, doi: 10.18433/J3X61S.
  18. Al-khazragie, Z. K., Al-salami, B. K. & Al-fartosy, A. J. M. Synthesis , Characterization , and Antioxidant , Antimicrobial and Toxic Derivatives. (2022) doi:10.25258/ijddt.12.1.22.